Xenetic Biosciences (XBIO) Common Equity (2011 - 2026)
Xenetic Biosciences' (XBIO) quarterly Common Equity came in at $7.0 million in Q1 2026, up 35.67% YoY from $5.1 million in Q1 2025, and down 6.02% on a QoQ basis from $7.4 million in Q4 2025.
Xenetic Biosciences (XBIO) Common Equity (2011 - 2026) Analysis & Trends
Xenetic Biosciences (XBIO) has 16 years of Common Equity data on file, last reported at $7.0 million in Q1 2026.
- Quarterly Common Equity rose 35.67% year-over-year to $7.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.0 million (up 35.67% YoY) and the FY2025 annual result came in at $7.4 million, up 23.12% from the prior year.
- Common Equity declined to $7.0 million in Q1 2026, from $7.4 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $16.9 million in Q1 2022 to a low of $4.0 million in Q3 2025.
- A 5-year average of $9.6 million and a median of $8.7 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity surged 54.58% — and 2025, when it sank 43.78%.
- Tracing XBIO's Common Equity over 5 years: stood at $13.6 million in 2022, then slipped by 28.22% to $9.8 million in 2023, then tumbled by 38.67% to $6.0 million in 2024, then increased by 23.12% to $7.4 million in 2025, then slipped by 6.02% to $7.0 million in 2026.
- The last three Common Equity figures came in at $7.0 million (Q1 2026), $7.4 million (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Xenetic Biosciences | 7.59 Mn | 1.12 Mn | - | 6.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.07 Mn |
| Mar 31, 2026 | 6.95 Mn |
| Dec 31, 2025 | 7.40 Mn |
| Sep 30, 2025 | 3.96 Mn |
| Jun 30, 2025 | 4.45 Mn |
| Mar 31, 2025 | 5.12 Mn |
| Dec 31, 2024 | 6.01 Mn |
| Sep 30, 2024 | 7.04 Mn |
| Jun 30, 2024 | 7.45 Mn |
| Mar 31, 2024 | 8.68 Mn |
| Dec 31, 2023 | 9.80 Mn |
| Sep 30, 2023 | 10.89 Mn |
| Jun 30, 2023 | 11.88 Mn |
| Mar 31, 2023 | 12.86 Mn |
| Dec 31, 2022 | 13.65 Mn |
| Sep 30, 2022 | 14.52 Mn |
| Jun 30, 2022 | 15.19 Mn |
| Mar 31, 2022 | 16.92 Mn |
| Dec 31, 2021 | 18.39 Mn |
| Sep 30, 2021 | 20.16 Mn |